Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages

Exagen Inc. (NASDAQ:XGN) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $13.8333.

Several analysts have recently issued reports on the company. BTIG Research upped their price target on Exagen from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. B. Riley reaffirmed a “buy” rating and set a $18.00 target price (up previously from $15.00) on shares of Exagen in a research report on Wednesday. Canaccord Genuity Group lifted their price target on shares of Exagen from $11.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price objective on shares of Exagen in a report on Wednesday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, October 8th.

Insider Activity at Exagen

In related news, CEO John Aballi sold 31,787 shares of the business’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $11.82, for a total transaction of $375,722.34. Following the completion of the transaction, the chief executive officer owned 714,427 shares of the company’s stock, valued at approximately $8,444,527.14. The trade was a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC boosted its holdings in Exagen by 10.3% during the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after purchasing an additional 2,600 shares in the last quarter. Calamos Advisors LLC lifted its position in shares of Exagen by 3.5% during the 3rd quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock worth $858,000 after buying an additional 2,677 shares during the period. Huntleigh Advisors Inc. boosted its stake in Exagen by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company’s stock valued at $613,000 after buying an additional 4,753 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Exagen in the first quarter valued at $25,000. Finally, Kennedy Capital Management LLC grew its position in Exagen by 5.3% in the second quarter. Kennedy Capital Management LLC now owns 310,721 shares of the company’s stock valued at $2,169,000 after acquiring an additional 15,568 shares during the period. 75.25% of the stock is owned by institutional investors.

Exagen Stock Performance

XGN stock opened at $10.38 on Friday. The firm has a 50 day moving average of $10.70 and a two-hundred day moving average of $8.51. Exagen has a 12 month low of $2.43 and a 12 month high of $12.23. The company has a market capitalization of $235.21 million, a price-to-earnings ratio of -11.28 and a beta of 1.66. The company has a quick ratio of 4.95, a current ratio of 4.08 and a debt-to-equity ratio of 1.35.

Exagen (NASDAQ:XGN) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $17.24 million for the quarter, compared to the consensus estimate of $16.90 million. Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. Exagen has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Exagen will post -0.88 EPS for the current fiscal year.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).